Artificial Intelligence (AI) is one of the fastest-growing tech trends—and you don’t need a big budget to get involved. Some of the most exciting innovations are happening not in billion-dollar corporations, but in small-cap companies developing smart solutions with high upside potential. Yes, we’re talking about AI penny stocks under $1 dollar—low-cost investments with massive long-term opportunity.

In this blog, we’ll explore a few promising ASX AI stocks that are flying under the radar but could offer big growth potential for savvy investors. These aren’t just under $1 stocks—they’re smart plays in the AI revolution. Whether you’re new to the market or looking to diversify your tech portfolio, these tech penny stocks deserve a closer look.

Why AI Penny Stocks?

Let’s face it—AI is no longer just a futuristic buzzword. From automating tasks to powering life-saving diagnostics and revolutionizing language processing, AI is already deeply embedded in how the world works. According to PwC, AI is expected to contribute $15.7 trillion to the global economy by 2030.

While mega-cap AI shares like Nvidia and Microsoft are making headlines, there’s another corner of the market that could offer even greater percentage returns: machine learning stocks that are still in their early growth stages.

That’s where AI penny stocks under $1 dollar come in. These companies are typically high-risk, high-reward bets—but for investors with vision and patience, they can offer serious upside.

Let’s look at two ASX-listed AI shares that are bringing innovation to real-world problems while trading at low prices.

1. Artrya Ltd (ASX: AYA)

AI-Powered Heart Disease Diagnostics

Current Price: Under $1
Sector: Healthcare Tech (AI)
Product Focus: Coronary Heart Disease Detection

Artrya is a health-tech innovator applying artificial intelligence to cardiac diagnostics. Its core product, Salix® Coronary Anatomy, uses AI to analyze coronary CT scans and identify signs of coronary heart disease (CHD) faster and more accurately than traditional methods. That’s a big deal, especially in time-critical medical environments.

Key Milestones and Growth Drivers:

1. FDA 510(k) Clearance Expected by March 2025: This U.S. regulatory green light could be a game-changer, unlocking access to the world’s most lucrative healthcare market.
2. Strategic U.S. Partnerships: Collaborations with Northeast Georgia, Tanner Health, and Cone Health signal real demand in the U.S. hospital market.
3. Backed by Healthliant Ventures: A strategic investment from this healthcare fund enhances Artrya’s credibility and capital base.

Financial Snapshot (H1 FY2025):

Operating Cash Outflow: $4.06 million (YoY Improvement of 41.95%)
NET Loss: $7.44 million

With two more regulatory filings (Salix Plaque and FFR) planned and a fully funded SAPPHIRE clinical study underway, Artrya has positioned itself as a frontrunner among tech penny stocks focused on AI-driven health solutions.

2. Ai-Media Technologies (ASX: AIM)

Smart Captioning, Smarter Growth

Current Price: Under $1
Sector: Media-Tech
Product Focus: AI-based captioning and translation

Ai-Media is a global leader in captioning, transcription, and translation services. The company uses machine learning and AI to deliver real-time and recorded captioning solutions to schools, broadcasters, businesses, and governments. Accessibility is a rising global mandate—and Ai-Media is perfectly positioned to ride that wave.

Growth Catalysts:

1. Lexi 3.0: The latest update to Ai-Media’s proprietary AI captioning engine offers greater accuracy and efficiency using natural language processing (NLP). It’s a significant upgrade aimed at handling large-scale deployments.
2. Smart Lexi Launch: This hybrid model combines AI with human oversight for premium results, ideal for live broadcasts and sensitive content.
3. Expanding Partnerships: Collaborations with major broadcasters and tech companies are helping Ai-Media scale globally.

Financial Snapshot (H1 FY2025):

Total Revenue: $31.79 million

Operating Cash Flow: $3.35 million
Strong internal cash generation, even with modest revenue growth, indicates operational stability and the ability to invest in future expansion.

As AI tools like ChatGPT have normalized automation across industries, demand for real-time, AI-based content services is rising sharply. Combine that with tightening global accessibility regulations—like the ADA in the U.S. and the AVMSD in Europe—and you’ve got a recipe for sustained demand. Ai-Media is one of the few ASX AI stocks directly positioned to benefit.

Why These AI Shares Stand Out

Both Artrya and Ai-Media represent distinct opportunities in the tech penny stocks category:

Artrya is tackling a high-stakes medical issue with cutting-edge diagnostics. The upcoming FDA decision could significantly re-rate the stock.

Ai-Media is already profitable at an operational level, with scalable, in-demand products and a global footprint.

And the best part? Both are ai penny stocks under $1 dollar, giving retail investors access to growth opportunities often reserved for early-stage venture capitalists.

Are You Ready to Think Small but Smart?

Investing in machine learning stocks at the penny level requires patience and due diligence—but the potential rewards are substantial. Both Artrya and Ai-Media show that innovation and impact don’t always come with a hefty price tag. In fact, these under $1 stocks could be your ticket into the fast-evolving AI landscape without breaking the bank.

As always, remember that penny stocks come with risk. But if you’re looking for exposure to ASX AI stocks with visionary leadership, clear product-market fit, and room to grow—Artrya and Ai-Media are names to keep on your radar.

Start small. Think smart. Watch the future unfold.

Disclaimer:

General Financial Product Advice and Regulatory Framework: Pristine Gaze Pty Ltd (ABN 66 680 815 678, ACN 680 815 678) operates as Corporate Authorised Representative (CAR No. 001312049) of Alpha Securities Pty Ltd (AFSL 330757), which is licensed and regulated by the Australian Securities and Investments Commission under the Corporations Act 2001 (Cth). This report contains general financial product advice only and has been prepared without consideration of your personal objectives, financial situation, specific needs, circumstances, or investment experience. The information is not tailored to individual circumstances and may not be suitable for your particular situation. Before acting on any information contained herein, you should carefully consider its appropriateness having regard to your personal objectives, financial situation, and needs, and consider seeking personal financial advice from a qualified financial adviser who can assess your individual circumstances and provide tailored recommendations.

Investment Risks and Market Warnings: All investments carry significant risk, and different investment strategies may carry varying levels of risk exposure including total loss of invested capital. The value of investments and income derived from them can fluctuate significantly due to market conditions, economic factors, company-specific events, regulatory changes, commodity price volatility, currency fluctuations, interest rate movements, and other factors beyond our control. Securities markets are subject to market risk from general economic conditions and investor sentiment, liquidity risk affecting the ability to buy or sell securities at desired prices, credit risk from issuer default or deterioration, operational risk from inadequate internal processes, sector-specific risks including industry regulatory changes, technology obsolescence, management changes, competitive pressures, supply chain disruptions, and mining-specific risks including resource estimation uncertainty, operational hazards, environmental compliance, permitting delays, commodity price cycles, geopolitical factors affecting mining operations, and exploration risks. Small-cap and speculative mining stocks carry additional risks including limited liquidity, higher volatility, dependence on key personnel, limited operating history, uncertain cash flows, and potential failure to achieve commercial production.

Information Accuracy and Limitations: While we endeavour to ensure information accuracy and reliability, we make no representations or warranties (express or implied) regarding the accuracy, reliability, completeness, timeliness, or suitability of information provided, except where liability cannot be excluded under applicable law. This report may include information from third-party sources including company announcements, regulatory filings, research reports, market data providers, financial news services, and publicly available information, which we do not independently verify and for which we assume no responsibility. Past performance, examples, historical data, or projections are not indicative of future results, and no guarantee of future returns is provided or implied. To the maximum extent permitted by law, Pristine Gaze Pty Ltd and Alpha Securities Pty Ltd, together with their respective directors, officers, employees, representatives, and related entities, exclude all liability for any errors, omissions, inaccuracies, loss or damage (including direct, indirect, consequential, or special damages) arising from reliance on information provided, investment decisions made based on this report, market losses, opportunity costs, and technical issues or system failures.